Drug intelligence / Profile preview

IQ-1

Development stage
Unknown
Lead developer
University of Southern California
Modality
Small Molecules
01

Overview

IQ-1 is a cell-permeable small-molecule modulator of the Wnt/β-catenin signaling pathway. It acts by binding to the PR72/130 (PPP2R3A) regulatory subunit of protein phosphatase 2A (PP2A), which blocks the interaction between PP2A and Naked cuticle (Nkd). This blockade prevents the PP2A-mediated dephosphorylation of the coactivator p300 (EP300) at Ser89, thereby disrupting the β-catenin/p300 interaction and preventing the switch of β-catenin coactivator usage from CBP (CREBBP) to p300. Consequently, IQ-1 selectively enhances β-catenin/CBP-mediated transcription at the expense of β-catenin/p300-mediated transcription. This mechanism is widely used in stem cell research to maintain the pluripotency and self-renewal of embryonic stem cells (ESCs) in vitro, and has been investigated for its ability to rescue hematopoietic stem cell (HSC) repopulating activity.

Other names
2-(4-Acetylphenylazo)-2-(3,3-dimethyl-3,4-dihydro-2H-isoquinolin-1-ylidene)-acetamide2-[2-(4-acetylphenyl)diazenyl]-2-(3,4-dihydro-3,3-dimethyl-1(2H)-isoquinolinylidene)-acetamide2-[(4-acetylphenyl)hydrazinylidene]-2-(3,3-dimethyl-4H-isoquinolin-1-yl)acetamideIQ 1IQ1IQ-1Wnt Pathway Activator III
02

Targets

PPP2R2A (PP2A regulatory subunit B55 alpha)

Beyond the preview

Go deeper on IQ-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on IQ-1.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call